Medical Complications | J.P. Morgan Private Bank Latin America

This Eye on the Market is about all the things that can be true at the same time. The collapse of the political middle in Congress should not be an excuse for everyone else to abandon the ability to believe things that may appear contradictory, but which are all part of a more complicated reality.

Line chart showing the decline in political moderates in the Senate and the House over time

Download the PDF

Watch the Podcast

Good afternoon, everybody, and welcome to the late January 2024 Eye On the Market. This one's called "Medical Complications." First, I want to make a quick introduction. This is Hobie, the dog. So hello, everyone. OK

So just a few quick things this time. First, in terms of why oil prices are so well-behaved, despite what's going on in the Red Sea, I would just quickly point out two things. Number one, over the long run and the short run, oil prices tend to be much more determined by the economic cycle in terms of growth, equity markets, and the strength of leading indicators than they are geopolitical risks, however you want to measure them. So I'm not surprised to see oil prices reasonably rangebound, despite what's going on in the Red Sea.

And the second thing to remember is the oil intensity of growth at this point, the oil intensity of GDP in the United States and other developed countries, is down 70% from what it was in the early '70s. And so every time there's a geopolitical issue, people immediately transport themselves back and remember the disaster in oil markets in the 1970s, but remember, in a slowly but gradually decarbonizing world, and more importantly, a world with greater energy efficiency of devices, furnaces, and combustion engines, the world is much less reliant on oil to grow.

Then real quick, I went on a trip to the West Coast. I went to San Francisco to participate in a VC gathering and to Salt Lake to present to some real estate clients. And real quick, the-- what I thought was interesting to share on the comments from the VC community was, first, on the '20 to 2021 vintages of investments, the comments were similar. There's a lot of losses still to come. There's a lot of dead money there and a lot of write-offs pending.

What's interesting is in the same breath, that was almost a universal belief that the next five years of VC investing was going to be the golden era for the VC community due in large part to AI, large language models, and things like that. So I thought it was interesting to see those two things juxtaposed with each other.

And then the third comment that was quite frequent was some frustration with Wall Street for dropping its coverage of so many small cap companies, which has made it more difficult for a lot of those VCs to exit through the IPO market.

And then in Utah, in a presentation to a national group of real estate developers, there was general consensus that office-to-residential conversions are an interesting topic to think about, with work from home still stuck at about 30% to 35% of workdays in a lot of large metropolitan areas, but that they're very difficult, very expensive. And we wrote about them in some detail a couple of months ago in our New York City study. And there was general consensus that you need some really big discounts in order to make the economics work. In other words, somebody acquiring an office building to do a residential conversion would really need a steep discount.

Interestingly enough, last week, a building on 55th and Broadway in Manhattan that was owned by one of the big institutional real estate companies-- its appraisal is now down 70% from 2014 levels after one of the big tenants vacated 60% or 70% of the space. So while some of these conversions are complicated, they take a long time, they're very expensive, if we start seeing 60% to 70% sales discounts on some of these downtown office buildings, that could make some of the conversions work.

And then one last comment about Utah. I had my first-ever chicken-- Chick-fil-A chicken sandwich, and-- you know, I'm 61. And I had my first-ever Chick-fil-A sandwich. And it was actually pretty good. I liked it a lot.

OK. So the main topic of today's podcast is about all the things that can be true at the same time, even though they might seem contradictory. And I started the discussion in the Eye in the Market with this chart about how the political middle in Congress has disappeared and is at its-- basically, its lowest level since the beginning of the republic, or close to it.

And in an-- when members of Congress really can only see one shade of any color, that doesn't absolve the rest of us. The rest of us need to be able to look at things, evaluate them for what they are, and believe certain things to be true, even if on their face some of them might seem a little bit contradictory.

And the reason I'm bringing this up is because of where we stand in the COVID pandemic and some of the broader issues related to vaccines, vaccine safety, and things like that. So I'm just going to give you the taglines. I really want people-- if you're interested in this topic, read the piece. Everything I'm about to tell you is deeply substantiated and researched in the piece itself, but here are the taglines.

The cost of COVID lockdowns in the United States is going to linger for years, and maybe decades, specifically as it relates to school-aged children, whose math and reading scores were set back 20 years from lockdowns. The FDA has recalled major drugs and has issued black box, which are severity warnings, on others. You've probably heard or have taken many of these drugs.

On top of that, drug company unlawful activity, whether it's kickbacks or bribes or illegal marketing or things like that or the opioid epidemic, have eroded public perception of the industry, which is a shame, because it tends to result in less confidence in drugs and vaccines, less participation in clinical trials, and even things like less adherence to people taking their proper medications.

You wouldn't know it by listening to sports talk shows or reading Twitter, but vaccines have had amazing success over the last hundred years in reducing their frequency of preventable diseases, many of which have either been eradicated or the incidence of people getting them and dying from them is down 95% to 99% compared to where we were 100 years ago. And despite that, vaccination trends have been declining in the United States a little bit, leading to an increase in measles outbreaks.

Now, the good news there is both of those cohorts still benefit from some degree of immunity, which is why hospitalization rates right now are pretty low. In other words, if you had been unvaccinated but also infected, you have what's called acquired immunity, or you could have vaccine-induced immunity, or you could have both.

So the good news is despite lower protection from those original vaccines and boosters, hospitalization rates are down because of that lingering immunity benefit. That said, the latest booster, right now, the XBB booster, is not really protective at all against infection, but is highly effective at preventing serious disease and more protective than being unboosted.

So all of these things are true at the same time. And I find it kind of remarkable that there are so many people in the public arena and in particular in social media that can't seem-- they just can't seem to grasp the reality that all of these things are simultaneous true and that you can't just grasp onto one of these factoids and say, well, therefore, that's the entire picture.

The other thing to keep in mind is the COVID vaccines and boosters reduce the risks of getting long COVID, which you do not want to get. And one of the things that we have in the piece is an explanation of what tends to happen to you if you get long COVID.

Now, to be clear, the mRNA vaccines are not riskless. There are risks of myocarditis and pericarditis, and right now, they're-- the percentage risk of those things is very well established. And the Trojan horse vector vaccines, whether it was AstraZeneca or J&J, they're not riskless, either, and then the very rare condition that has resulted from those is even more serious, and the J&J vaccine is not even available anymore in the United States because of it.

But to be clear, the blood clot risk from getting COVID is a lot greater than the blood clot risk from receiving the vaccine itself, another factor which is pretty well established. And then as it relates to all of these reported instances of cardiac arrest and sudden death, they-- every time they get evaluated in autopsies, they're not attributed to COVID vaccines, despite all the stuff that you read on Twitter and in books that are published by Children's Health Defense and other opponents of vaccination.

And the last point I would make on this topic is in either February or March of 2020, there was a paper called "Proximal Origin." It completely dismissed out of hand the possibility of COVID lab origins barely one month into the pandemic. I think at this point, it's pretty clear that based on all sorts of problems with its production, its assumptions, and its biases, that paper should be officially withdrawn by the journal that published it, or even better, by the by the people that wrote it.

But anyway, if you're interested in any of these topics, we go into them in some degree of detail in this week's Eye on the Market. And so that is all for now.

We've got a piece coming up on what's next for artificial intelligence, if you're interested in things like subquadratic scaling, which could render transformers less important at some point in the future. And then, of course, our energy piece comes out in early March. Thanks, everybody, for listening, and hope and wish you all a great week. Bye.

(DESCRIPTION)

Text, J.P. Morgan, The views and strategies described herein may not be suitable for all clients and are subject to investment risks. Certain opinions, estimates, investment strategies and views expressed in this document constitute our judgment based on current market conditions and are subject to change without notice. This material should not be regarded as research or as a J.P. Morgan research report. The information contained herein should not be relied upon in isolation for the purpose of making an investment decision. More complete information is available, including product profiles, which discuss risks, benefits, liquidity and other matters of interest. For more information on any of the investment ideas and products illustrated herein, please contact your J.P. Morgan representative. Investors may get back less than they invested, and past performance is not a reliable indicator of future results.

Investment and Insurance Products: Not a Deposit. Not F,D,I,C Insured. Not Insured by any Federal Government Agency. No Bank Guarantee. May Lose Value.

J P Morgan Chase Bank, N.A., and its affiliates (collectively "J,P,M,C,B") offer investment products, which may include bank-managed accounts and custody as part of its trust and fiduciary services. Other investment products and services, such as brokerage and advisory accounts, are offered through J P Morgan Securities, L,L,C (J,P,M,S), a member of FINRA and S,I,P,C. J,P,M,C,B and J,P,M,S are affiliated companies under the common control of J P Morgan Chase and Company. The views expressed herein may differ from other J P Morgan Chase & Co affiliates and employees. This constitutes our judgment based on current market conditions and is subject to change without notice. This has not been prepared with any particular investor in mind, and it may not be suitable for all investors. Investors should speak to their financial representatives before engaging in any investment product or strategy. This material should not be regarded as research or as a J P Morgan Research Report. Outlooks and past performance are not reliable indicators of future results.

Title, Podcast: Medical Complications, Michael Cembalest, Chairman of Market and Investment Strategy, J P Morgan Asset and Wealth Management, January 2024. The speaker appears on an inset screen at the top right corner.

(SPEECH)

Good afternoon, everybody, and welcome to the late January 2024 Eye on The Market. This one's called Medical Complications. First, I want to make a quick introduction. This is Hobie the dog.

(DESCRIPTION)

He holds up Hobie, a dog that has floppy ears and light, wiry fur. Then he sets Hobie down.

(SPEECH)

So hello, everyone.

OK, so just a few quick things this time. First, in terms of why oil prices are so well-behaved despite what's going on in the Red Sea, I would just quickly point out two things. Number one, over the long run and the short run, oil prices tend to be much more determined by the economic cycle in terms of growth, equity markets, and the strength of leading indicators than they are geopolitical risks however you want to measure them. So I'm not surprised to see oil prices reasonably rangebound despite what's going on in the Red Sea.

And the second thing to remember is the oil intensity of growth at this point, the oil intensity of GDP in the United States and other developed countries is down 70% from what it was in the early '70s. And so every time there's a geopolitical issue, people immediately transport themselves back and remember the disaster in oil markets in the 1970s. But remember, in a slowly but gradually decarbonizing world, and more importantly, a world with greater energy efficiency of devices, furnaces, and combustion engines, the world is much less reliant on oil to grow.

(DESCRIPTION)

Text, West Coast trip, VC comments on 2020 to 2021 vintages, the next 5 years of VC investing and Wall Street coverage of small cap companies. Office to residential conversions. Chick Fil A

(SPEECH)

Real quick, I went on a trip to the West Coast. I went to San Francisco to participate in a VC gathering and to Salt Lake to present to some real estate clients. And real quick, what I thought was interesting to share on the comments from the VC community was first, on the '20 to 2021 vintages of investments, the comments were similar, there's a lot of losses still to come, there's a lot of dead money there, and a lot of write-offs pending.

What's interesting is in the same breath there was almost a universal belief that the next five years of VC investing was going to be the golden era for the VC community, due in large part to AI, large language models, and things like that. So I thought it was interesting to see those two things juxtaposed with each other.

And then the third comment that was quite frequent was some frustration with Wall Street for dropping its coverage of so many small-cap companies, which has made it more difficult for a lot of those VCs to exit through the IPO market.

And then, in Utah, in a presentation to a national group of real estate developers, there was general consensus that office-to-residential conversions are an interesting topic to think about with work-from-home still stuck at about 30% to 35% of workdays in a lot of large metropolitan areas but that they're very difficult, very expensive. And we wrote about them in some detail a couple of months ago in our New York City study. And there was general consensus that you need some really big discounts in order to make the economics work. In other words, somebody acquiring an office building to do a residential conversion would really need a steep discount.

Interestingly enough, last week, a building on 55th and Broadway in Manhattan that was owned by one of the big institutional real estate companies, its appraisal is now down 70% from 2014 levels after one of the big tenants vacated 60% or 70% of the space. So while some of these conversions are complicated, they take a long time, they're very expensive, if we start seeing 60% to 70% sales discounts on some of these downtown office buildings, that could make some of the conversions work.

And then one last comment about Utah, I had my first-ever Chick-fil-A chicken sandwich. And I'm 61, and I had my first-ever Chick-fil-A sandwich, and it was actually pretty good. I liked it a lot.

(DESCRIPTION)

A line graph appears. Text, The middle, Source, J,P,M,A,M, Voter view dot com, data through 117th congress ending in 2023. Moderates defined as Nokken-Poole Voter view scores from minus 0.25 to plus 0.25

(SPEECH)

OK, so the main topic of today's podcast is about all the things that can be true at the same time even though they might seem contradictory. And I started the discussion in the Eye On the Market with this chart about how the political middle in Congress has disappeared and is at basically its lowest level since the beginning of the Republic or close to it. And when members of Congress really can only see one shade of any color, that doesn't absolve the rest of us. The rest of us need to be able to look at things, evaluate them for what they are, and believe certain things to be true even on their face some of them might seem a little bit contradictory.

And the reason I'm bringing this up is because of where we stand in the COVID pandemic and some of the broader issues related to vaccines, vaccine safety, and things like that. So I'm just going to give you the taglines. I really want people if you're interested in this topic, read the piece, everything I'm about to tell you is deeply substantiated and researched in the piece itself, but here are the taglines.

(DESCRIPTION)

Text, Medical Complications

(SPEECH)

The cost of COVID lockdowns in the United States is going to linger for years and maybe decades. Specifically, as it relates to school-aged children whose math and reading scores were set back 20 years from lockdowns.

The FDA has recalled major drugs and has issued black box, which are severity warnings on others. You've probably heard or have taken many of these drugs. On top of that, drug company unlawful activity, whether it's kickbacks or bribes or illegal marketing or things like that or the opioid epidemic have eroded public perception of the industry, which is a shame because it tends to result in less confidence in drugs and vaccines, less participation in clinical trials, and even things like less adherence to people taking their proper medications.

You wouldn't know it by listening to sports talk shows or reading Twitter but vaccines have had amazing success over the last 100 years in reducing the frequency of preventable diseases, many of which have either been eradicated, or the incidence of people getting them and dying from them is down 95% to 99% compared to where we were 100 years ago. And despite that, vaccination trends have been declining in the United States a little bit, leading to an increase in measles outbreaks.

The original-- now let's talk about the COVID vaccines. The original COVID vaccines, and then the Omicron boosters, were very effective in 2021 and 2022 at preventing serious illness. That protection waned over time as the virus mutated. This virus happens to mutate I think 2 and 1/2 times faster than the flu and seven times faster than other coronaviruses. And those mutations have now rendered the protection that you would be getting from the original vaccine and the Omicron boosters as not being that different from being unvaccinated. Now, the good news there is both of those cohorts still benefit from some degree of immunity which is why hospitalization rates right now are pretty low. In other words, if you had been unvaccinated but also infected, you have what's called acquired immunity, or you could have vaccine-induced immunity, or you could have both.

So the good news is, despite lower protection from those original vaccines and boosters, hospitalization rates are down because of that lingering immunity benefit. That said, the latest booster right now, the XBB booster, is not really protective at all against infection but is highly effective at preventing serious disease and more protective than being unboosted.

So all of these things are true at the same time. And I find it kind of remarkable that there are so many people in the public arena, and in particular, in social media, that can't seem-- they just can't seem to grasp the reality that all of these things are simultaneously true and that you can't just grasp onto one of these factoids and say, well, therefore, that's the entire picture.

Now, to be clear, the mRNA vaccines are not riskless. There are risks of myocarditis and pericarditis. And right now the percentage risk of those things is very well established, and the Trojan horse vector vaccines, whether it was AstraZeneca or J&J, they're not riskless either. And the very rare condition that has resulted from those is even more serious and the J&J vaccine is not even available anymore in the United States because of it. But to be clear, the blood clot risk from getting COVID is a lot greater than the blood clot risk from receiving the vaccine itself, another fact which is pretty well established.

And then as it relates to all of these reported instances of cardiac arrest and sudden death, every time they get evaluated in autopsies they're not attributed to COVID vaccines despite all the stuff that you read on Twitter and in books that are published by Children's Health Defense and other opponents of vaccination.

And the last point I would make on this topic is in either February or March of 2020 there was a paper called Proximal Origin. It completely dismissed out of hand the possibility of COVID lab origins barely one month into the pandemic. I think at this point, it's pretty clear that based on all sorts of problems with its production, its assumptions, and its biases, that paper should be officially withdrawn by the journal that published it or even better by the people that wrote it. And but anyway, if you're interested in any of these topics we go into them in some degree of detail in this week's Eye on the Market. And so that is all for now.

We've got a piece coming up on what's next for artificial intelligence, if you're interested in things like subquadratic scaling, which could render transformers less important at some point in the future. And then, of course, our energy piece comes out in early March. Thanks, everybody for listening, and Hobie and I wish you all a great week. Bye.

(DESCRIPTION)

Logo, J P Morgan

Disclaimer: IMPORTANT INFORMATION. This report uses rigorous security protocols for selected data sourced from Chase credit and debit card transactions to ensure all information is kept confidential and secure. All selected data is highly aggregated and all unique identifiable information, including names, account numbers, addresses, dates of birth, and Social Security Numbers, is removed from the data before the report's author receives it. The data in this report is not representative of Chase's overall credit and debit cardholde population. The views, opinions and estimates expressed herein constitute Michael Cembalest's judgment based on current market conditions and are subject to change without notice. Information herein may differ from those expressed by other areas of J.P Morgan. This information in no way constitutes J.P. Morgan Research and should not be treated as such. The views contained herein are not to be taken as advice or a recommendation to buy or sell any investment in any jurisdiction, nor is it a commitment from J.P. Morgan or any of its subsidiaries to participate in any of the transactions mentioned herein. Any forecasts, figures, opinions or investment techniques and strategies set out are for information purposes only, based on certain assumptions and current market conditions and are subject to change without prior notice. All information presented herein is considered to be accurate at the time of production. This material does not contain sufficient information to support an investment decision and it should not be relied upon by you in evaluating the merits of investing in any securities or products. In addition, users should make an independent assessment of the legal, regulatory, tax, credit and accounting implications and determine, together with their own professional advisers, if any investment mentioned herein is believed to be suitable to their personal goals. Investors should ensure that they obtain all available relevant information before making any investment. It should be noted that investment involves risks, the value of investments and the income from them may fluctuate in accordance with market conditions and taxation agreements and investors may not get back the full amount invested. Both past performance and yields are not reliable indicators of current and future results. Non-affiliated entities mentioned are for informational purposes only and should not be construed as an endorsement or sponsorship of J.P. Morgan Chase & Co. or its affiliates.

For J.P. Morgan Asset Management Clients: J.P. Morgan Asset Management is the brand for the asset management business of J.P. Morgan Chase & Co. and its affiliates worldwide. To the extent permitted by applicable law, we may record telephone calls and monitor electronic communications to comply with our legal and regulatory obligations and internal policies. Personal data will be collected, stored and processed by J.P. Morgan Asset Management in accordance with our privacy policies at https://am.ipmoran.com/aleba/privacx. ACCESSIBILITY For U.S. only: If you are a person with a disability and need additional support in viewing the material, please call us at 1-800-343-1113 for assistance. This communication is issued by the following entities: In the United States, by J.P. Morgan Investment Management Inc. or J.P. Morgan Alternative Asset Management, Inc., both regulated by the Securities and Exchange Commission; in Latin America, for intended recipients' use only, by local J.P. Morgan entities, as the case may be.; in Canada, for institutional clients' use only, by J.P. Morgan Asset Management (Canada) Inc., which is a registered Portfolio Manager and Exempt Market Dealer in all Canadian provinces and territories except the Yukon and is also registered as an Investment Fund Manager in British Columbia, Ontario, Quebec and Newfoundland and Labrador. In the United Kingdom, by J.P. Morgan Asset Management (UK) Limited, which is authorized and regulated by the Financial Conduct Authority, in other European jurisdictions, by J.P. Morgan Asset Management (Europe) S.à r.I. In Asia Pacific ("APAC"), by the following issuing entities and in the respective jurisdictions in which they are primarily regulated J.P. Morgan Asset Management (Asia Pacific) Limited, or J.P. Morgan Funds (Asia) Limited, or J.P. Morgan Asset Management Real Assets (Asia) Limited, each of which is regulated by the Securities and Futures Commission of Hong Kong: J.P. Morgan Asset Management (Singapore) Limited (Co. Reg. No. 197601586K), which this advertisement or publication has not been reviewed by the Monetary Authority of Singapore; J.P. Morgan Asset Management (Taiwan) Limited; J.P. Morgan Asset Management (Japan) Limited, which is a member of the Investment Trusts Association, Japan, the Japan Investment Advisers Association, Type II Financial Instruments Firms Association and the Japan Securities Dealers Association and is regulated by the Financial Services Agency (registration number "Kanto Local Finance Bureau (Financial Instruments Firm) No. 3 3 0*); in Australia, to wholesale clients only as defined in section 761A and 7 6 1 G of the Corporations Act 2001 (Commonwealth), by J.P. Morgan Asset Management (Australia) Limited (ABN 5 5 1 4 3 8 3 2 0 8 0) (AFSL 3 7 6 9 1 9). For all other markets in APAC, to intended recipients only.

For J.P. Morgan Privato Bank Clients: ACCESSIBILITY. J.P. Morgan is committed to making our products and services accessible to meet the financial services needs of all our clients. Please direct any accessibility issues to the Private Bank Client Service Center at 1-866-265-1727. LEGAL ENTITY, BRAND & REGULATORY INFORMATION. In the United States, bank deposit accounts and related services, such as checking, savings and bank lending, are offered by J.P. Morgan Chase Bank, N.A. Member FDIC. business as Chase Insurance Agency Services, Inc. in Florida. JPMCB, JPMS and CIA are affiliated companies under the common control of JPM. Products not available in all states.

In Germany, this material is issued by J.P. Morgan SE, with its registered office at Taunustor 1 (Taunus Turm), 6 0 3 1 0 Frankfurt am Main, Germany, authorized by the Bundesanstalt für Finanzdienstleistungsaufsicht (BaFin) and jointly supervised by the BaFin, the German Central Bank (Deutsche Bundesbank) and the European Central Bank (ECB). In Luxembourg, this material is issued by J.P. Morgan SE - Luxembourg Branch, with registered office at European Bank and Business Centre, 6 route de Treves, L-2 6 3 3, Senningerberg, Luxembourg, authorized by the Bundesanstalt für Finanzdienstleistungsaufsicht (BaFin) and jointly supervised by the BaFin, the German Central Bank (Deutsche Bundesbank) and the European Central Bank (ECB): J.P. Morgan SE - Luxembourg Branch is also supervised by the Commission de Surveillance du Secteur Financier (CSSF); registered under R.C.S Luxembourg B 2 5 5 9 3 8. In the United Kingdom, this material is issued by J.P. Morgan SE - London Branch, registered office at 25 Bank Street, Canary Wharf, London E14 5JP, authorized by the Bundesanstalt für Finanzienstlelstungsaufsicht (BaFin) and jointly supervised by the BaFin, the German Central Bank (Deutsche Bundesbank) and the European Central Bank (ECB); J.P. Morgan SE - London Branch is also supervised by the Financial Conduct Authority and Prudential Regulation Authority. In Spain, this material is distributed by J.P. Morgan SE, Sucursal en España, with registered office at Paseo de la Castellana, 31, 2 8 0 4 6 Madrid, Spain, authorized by the Bundesanstalt für Finanzienstleistungsaufsicht (BaFin) and jointly supervised by the BaFin, the German Central Bank (Deutsche Bundesbank and the European Central Bank (ECB); J.P. Morgan SE, Sucursal en España is also supervised by the Spanish Securities Market Commission (CNMV): registered with Bank of Spain as a branch of J.P. Morgan SE under code 1 5 6 7.

In Italy, this material is distributed by J.P. Morgan S.E. - Milan Branch, with its registered office at Via Cordusio, n.3, Milan 20123, Italy, authorized by the Bundesanstalt für Finanzdienstleistungsaufsicht (BaFin) and jointly supervised by the BaFin, the German Central Bank (Deutsche Bundesbank) and the European Central Bank (ECB); J.P. Morgan SE - Milan Branch is also supervised by Bank of Italy and the Commissione Nazionale per le Società e la Borsa (CONSOB); registered with Bank of Italy as a branch of J.P. Morgan SE under code 8076; Milan Chamber of Commerce Registered Number: REA MI 2536325. In the Netherlands, this material is distributed by J.P. Morgan SE - Amsterdam Branch, with registered office at World Trade Centre, Tower B, Strawinskylaan 1 1 3 5, 1 0 7 7 XX, Amsterdam, The Netherlands, authorized by the Bundesanstalt für Finanzdienstleistungsaufsicht (BaFin) and jointly supervised by the BaFin, the German Central Bank (Deutsche Bundesbank) and the European Central Bank (ECB); J.P. Morgan SE - Amsterdam Branch is also supervised by De Nederlandsche Bank (DNB) and the Autorteit Financiele Markten (AFM) in the Netherlands. Registered with the Kamer van Koophandel as a branch of J.P. Morgan SE under registration number 7 2 6 1 0 2 2 0.

In Denmark, this material is distributed by J.P. Morgan SE - Copenhagen Branch, filial af J.P. Morgan SE, Tyskland, with registered office at Kalvebod Brygge 39-41, 1560 Kebenhavn V Denmark, authorized by the Bundesanstalt für Finanzienstleistungsaufsicht (BaFin) and jointly supervised by the BaFin, the German Central Bank (Deutsche Bundesbank) and the European Central Bank (ECB): J.P. Morgan SE - Copenhagen Branch, filial af J.P. Morgan SE, Tyskland is also supervised by Finanstisynet (Danish FSA) and is registered with Finanstilsynet as a branch of J.P. Morgan SE under code 2 9 0 1 0. In Sweden, this material is distributed by J.P. Morgan SE - Stockholm Bankfilial, with registered office at Hamngatan 15, Stockholm, 1 1 1 4 7, Sweden, authorized by the Bundesanstalt für Finanzienstleistungsaufsicht (BaFin) and jointly supervised by the BaFin, the German Central Bank (Deutsche Bundesbank) and the European Central Bank (ECB): J.P. Morgan SE - Stockholm Bankfilial is also supervised by Finansinspektionen (Swedish FSA); registered with Finansinspektionen as a branch of J.P. Morgan SE. In France, this material is distributed by J.P. Morgan Chase Bank, N.A.-Paris Branch, registered office at 14,Place Vendome, Paris 75001, France, registered at the Registry of the Commercial Court of Paris under number 7 1 2 0 4 1 3 3 4 and licensed by the Autorité de contrôle prudentiel et de resolution (ACPR) and supervised by the ACPR and the Autorité des Marchés Financiers. In Switzerland, this material is distributed by J.P. Morgan (Suisse) SA, with registered address at rue du Rhône, 35, 1 2 0 4, Geneva Switzerland, which is authorised and supervised by the Swiss Financial Market Supervisory Authority (FINMA) as a bank and a securities dealer in Switzerland.

In Hong Kong, this material is distributed by JPMCB, Hong Kong branch. JPMCB, Hong Kong branch is regulated by the Hong Kong Monetary Authority and the Securities and Futures Commission of Hong Kong. In Hong Kong, we will cease to use your personal data for our marketing purposes without charge if you so request. In Singapore, this material is distributed by JPMCB, Singapore branch. JPMCB, Singapore branch is regulated by the Monetary Authority of Singapore. Dealing and advisory services and discretionary investment management services are provided to you by JPMCB, Hong Kong/Singapore branch (as notified to you). Banking and custody services are provided to you by JPMCB Singapore Branch. The contents of this document have not been reviewed by any regulatory authority in Hong Kong, Singapore or any other jurisdictions. You are advised to exercise caution in relation to this document. If you are in any doubt about any of the contents of this document, you should obtain independent professional advice. For materials which constitute product advertisement under the Securities and Futures Act and the Financial Advisers Act, this advertisement has not been reviewed by the Monetary Authority of Singapore. J.P. Morgan Chase Bank, NA., a national banking association chartered under the laws of the United States, and as a body corporate, its shareholder's liability is limited. With respect to countries in Latin America, the distribution of this material may be restricted in certain jurisdictions. We may offer and/or sell to you securities or other financial instruments which may not be registered under, and are not the subject of a public offering under, the securities or other financial regulatory laws of your home country. Such securities or instruments are offered and/or sold to you on a private basis only. Any communication by us to you regarding such securities or instruments, including without limitation the delivery of a prospectus, term sheet or other offering document, is not intended by us as an offer to sell or a solicitation of an offer to buy any securities or instruments in any jurisdiction in which such an offer or a solicitation is unlawful. Furthermore, such securities or instruments may be subject to certain regulatory and/or contractual restrictions on subsequent transfer by you, and you are solely responsible for ascertaining and complying with such restrictions. To the extent this content makes reference to a fund, the Fund may not be publicly offered in any Latin American country, without previous registration of such fund's securities in compliance with the laws of the corresponding jurisdiction. Public offering of any security including the shares of the Fund, without previous registration at Brazilian Securities and Exchange Commission - CVM is completely prohibited. Some products or services contained in the materials might not be currently provided by the Brazilian and Mexican platforms.

References to "J.P. Morgan" are to JPM, its subsidiaries and affiliates worldwide. "J.P. Morgan Private Bank" is the brand name for the private banking business conducted by JPM. This material is intended for your personal use and should not be circulated to or used by any other person, or duplicated for non-personal use, without our permission. If you have any questions or no longer wish to receive these communications, please contact your J.P. Morgan team. J.P. Morgan Chase Bank, N.A. (JPMCBNA) (ABN 4 3 0 7 4 1 1 2 0 1 1 / AFS Licence No: 2 3 8 3 6 7) is regulated by the Australian Securities and Investment Commission and the Australian Prudential Regulation Authority. Material provided by JPMCBNA in Australia is to wholesale clients" only. For the purposes of this paragraph the term "Wholesale client" has the meaning given in section 761G of the Corporations Act 2001 (Cth). Please inform us if you are not a Wholesale Client now or if you cease to be a Wholesale Client at any time in the future. JPMS is a registered foreign company (overseas) (ARBN 109293610) incorporated in Delaware, U.S.A. Under Australian financial services licensing requirements, carrying on a financial services business in Australia requires a financial service provider such as J.P. Morgan Securities LLC (JPMS), to hold an Australian Financial Services Licence (AFSL), unless an exemption applies. JPMS is exempt from the requirement to hold an AFSL under the Corporations Act 2001 (Cth) (Act) in respect of financial services it provides to you, and is regulated by the SEC, FINRA and CFTC under US laws, which differ from Australian laws. Material provided by JPMS in Australia is to "wholesale clients" only. The information provided in this material is not intended to be, and must not be, distributed or passed on, directly or indirectly, to any other class of persons in Australia. For the purposes of this paragraph the term wholesale client" has the meaning given in section 761G of the Act. Please inform us immediately if you are not a Wholesale Client now or if you cease to be a Wholesale Client at any time in the future. This material has not been prepared specifically for Australian investors. It: - may contain references to dollar amounts which are not Australian dollars: - may contain financial information which is not prepared in accordance with Australian law or practices; - may not address risks associated with investment in foreign currency denominated investments; and - does not address Australian tax issues. © 2023 J.P. Morgan Chase & Co. All rights reserved.

For J.P. Morgan Wealth Management Clients: Purpose of this material: This material is for informational purposes only. The views, opinions, estimates, and strategies expressed herein constitute's Michael Cembalest's judgment based on current market conditions and are subject to change without notice, and may differ from those expressed by other areas of J.P. Morgan. This information in no way constitutes J.P. Morgan Research and should not be treated as such. J.P. Morgan is committed to making our products and services accessible to meet the financial services needs of all our clients. If you are a person with a disability and need additional support, please contact your J.P. Morgan representative or email us at accessibility.support@ipmorgan.com for assistance. J.P. Morgan Wealth Management is a business of JP Morgan Chase & Co., which offers investment products and services through J.P. Morgan Seccurities LLC (JPMS), a registered broker-dealer and investment advisor, member FINRA and SIPC.. Annuities are made available through Chase Insurance Agency Inc., (C.I.A.), a licensed insurance agency, doing business as Chase Insurance agency Services Inc. in Florida. Certain custody and other services are provided by JP Morgan Chase Bank, N.A. (JPMCB), JPMS, CIA and JPMCB are affiliated companies under the common control of J.P. Morgan Chase & Co. Products not available in all states. This material is intended for your personal use and should not be circulated to or used by any other person, or duplicated for non-personal use, without our permission. If you have any questions or no longer wish to receive these communications, please contact your J.P. Morgan representative.

LEGAL ENTITY, BRAND & REGULATORY INFORMATION. The views, opinions and estimates expressed herein constitute Michael Cembalest's judgment based on current market conditions and are subject to change without notice. Information herein may differ from those expressed by other areas of J.P. Morgan. This information in no way constitutes J.P. Morgan Research and should not be treated as such. The views contained herein are not to be taken as an advice or a recommendation to buy or sell any investment in any jurisdiction and there is no guarantee that any of the views expressed will materialize. Any forecasts, figures, opinions or investment techniques and strategies set out are for information purposes only, based on certain assumptions, current market conditions and are subject to change without prior notice. All information presented herein is considered to be accurate at the time of writing, but no warranty of accuracy is given and no liability in respect of any error or omission is accepted. This material does not contain sufficient information to support an investment decision and it should not be relied upon by you in evaluating the merits of investing in any securities or products. In addition, investors should make an independent assessment of the legal, regulatory, tax, credit, and accounting implications and determine, together with their own professional advisers, if any investment mentioned herein is believed to be suitable to their personal goals. Investors should ensure that they obtain all available relevant information before making any investment. It should be noted that investment involves risks, the value of investments and the income from them may fluctuate in accordance with market conditions and investors may not get back the full amount invested. Both past performance and yield may not be a reliable guide to future performance. Non-affiliated entities mentioned are for informational purposes only and should not be construed as an endorsement or sponsorship of J.P. Morgan Chase & Co. or its affiliates. J.P. Morgan Wealth Management is the brand for the wealth management business of J.P. Morgan Chase & Co. and its affiliates worldwide. J.P. Morgan Institutional Investments, Inc.. For J.P. Morgan Private Bank Clients: Please read the Legal Disclaimer. For J.P. Morgan Asset Management Clients: Please read the Legal Disclaimer For J.P. Morgan Wealth Management Clients: Please read the Legal Disclaimer For Chase Private Clients: Please read the egal Disclaimer.